Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Carbenicillin is a semisynthetic, broad-spectrum penicillin antibiotic (carboxypenicillin) used parenterally to treat infections, especially those due to Gram-negative bacteria such as Pseudomonas aeruginosa and Escherichia coli. It acts by interfering with bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), inhibiting peptidoglycan cross-linking. Carbenicillin is acid labile and more resistant to beta-lactamase than ampicillin, but can still be degraded by these enzymes. It may cause dose-dependent side effects, such as bleeding and hypokalemia, and is used in research settings as a selection agent in molecular biology due to lower toxicity of its breakdown products.
Inhibitor of bacterial cell wall synthesis (by binding to penicillin-binding proteins (PBPs) and blocking peptidoglycan crosslinking)
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Carbenicillin.